Skip to content
20-F

Annual Report (Foreign)

Regencell Bioscience Holdings Limited RGC

0001013762-23-007289

← back to feed
Filed
Oct 27, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Jun 30, 2023 13.01M sh
Short Term Investments FY 2023 · Jun 30, 2022 $10M
Stockholders Equity FY 2023 · Jun 30, 2022 $17.07M
Current Liabilities FY 2023 · Jun 30, 2022 $577.76K
Total Liabilities FY 2023 · Jun 30, 2022 $938.03K
Current Assets FY 2023 · Jun 30, 2022 $16.44M
Total Assets FY 2023 · Jun 30, 2022 $18.02M
Shares Diluted FY 2023 · Jun 30, 2021 10M sh
Operating Cash Flow FY 2023 · Jun 30, 2021 −$767.31K
Eps Diluted FY 2023 · Jun 30, 2021 −$0.13
Eps Basic FY 2023 · Jun 30, 2021 $0.13
Sga Expense FY 2023 · Jun 30, 2021 $941.46K
Rd Expense FY 2023 · Jun 30, 2021 $438.32K
Net Income FY 2023 · Jun 30, 2021 −$1.35M
Operating Income FY 2023 · Jun 30, 2021 −$1.38M
Short Term Debt FY 2023 · Feb 21, 2021 $3M